Drugs / SCB-1033
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06984094 | Jun 2025 → Mar 2028 expected | parainfluenza infectious disease, respiratory syncytial virus infectious disease | Clover Biopharmaceuticals AUS Pty | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-09-06 | Clover Biopharmaceuticals AUS Pty | Results Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults cloverbiopharma.com ↗
Robust neutralizing antibody responses across RSV, hMPV and PIV3 in Phase 2 recapitulates Phase 1 results demonstrating best-in-class breadth (with no immune interference) and no drop-off in responses in the oldest participants (75+ years) |
| 2025-10-14 | Clover Biopharmaceuticals AUS Pty | Results Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults cloverbiopharma.com ↗
Increases in neutralizing antibodies of approximately 6-8 fold for RSV, 6-9 fold for hMPV and 4 fold for PIV3 (≥10 fold increases in PIV3 PreF-specific antibodies) were observed |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-06 | Clover Biopharmaceuticals AUS Pty | Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults cloverbiopharma.com ↗ |
| 2025-10-14 | Clover Biopharmaceuticals AUS Pty | Clover Announces Positive Phase I Clinical Data for RSV-hMPV-PIV3 Combination Vaccines and for RSV Re-Vaccination in Older Adults cloverbiopharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCB-1033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06984094 ↗ |
| Modality | Vaccine | “SCB-1033 (combination recombinant RSV-hMPV-PIV3 vaccine candidate)” NCT06984094 ↗ |